Defence Therapeutics Partners with FMS Consult GmbH to Enhance Financial Strategy

Defence Therapeutics Inc., a Canadian biopharmaceutical company, announced a strategic partnership with FMS Consult GmbH, a European corporate financing consulting firm. This collaboration aims to bolster Defence's financial strategy to support its expanding product pipeline. As a clinical-stage oncology company, Defence is advancing its lead technology, the Accum® platform, which is significant in the development of cancer treatments including ADCs, cancer vaccines, and anti-cancer injectable drugs. CEO Sebastien Plouffe emphasized the importance of securing a knowledgeable financial advisor with a strong track record in the biotech sector to facilitate the company's growth.